Draft Industry Summary S02

Skill: Draft Industry Summary Memo for Diagnostics Acquisition

1. Subject-matter triage

• Treat the assignment as a cross-source diligence memo, not a pure market overview.
• Separate core market facts from deal-specific risks, then reconcile sell-side claims against independent research and internal strategy notes.
• If the source set includes multiple markets, product lines, geographies, payor regimes, or transaction comps, enumerate them first and analyze each separately rather than blending them into one blended conclusion.
• If only one relevant customer, reimbursement event, regulatory regime, or comp set exists, state that explicitly and explain why no broader set is in scope.

2. Failure modes the skill is correcting

• Repeating sell-side market sizing, share, or growth claims without checking the base year, methodology, or independent confirmation.
• Treating an apparent market leader or high-growth segment as verified when the underlying source data are stale, selectively framed, or measured on inconsistent bases.
• Ignoring customer concentration when a major relationship is near renewal or expiration during the deal timeline.
• Describing reimbursement cuts, regulatory change, or certification delays qualitatively without translating them into financial impact.
• Assuming pipeline revenue as if early-stage products were near-commercial or fully de-risked.
• Using precedent transactions mechanically when older or atypical deals distort the median.
• Missing discrepancies between external materials and internal strategy documents on international revenue or OTC growth.

3. Legal frameworks / domain conventions that apply

• Customer concentration and renewal risk are material diligence points in healthcare diagnostics; identify the customer, the revenue exposure, the contract timing, and the transaction-window overlap, then explain the revenue and closing implications.
• Reimbursement reductions should be translated into revenue and EBITDA impact using the applicable revenue base and any documented offsetting cost changes; do not leave the effect at the narrative level.
• Laboratory-developed test regulatory change should be analyzed in light of the governing rule, any legal challenges, and any phased implementation; near-term impact may be overstated if compliance ramps gradually.
• EU in vitro diagnostics certification constraints should be assessed against the applicable conformity-assessment regime and the capacity of third-party reviewers; revenue forecasts that depend on new certification should be timing-risk adjusted.
• Recency-sensitive precedent transaction analysis should separate older or outlier deals from the relevant current market set and present both the unadjusted and adjusted benchmark where the difference is material.
• Pipeline products must be described at their actual development stage; feasibility-stage products are pre-commercial and should not be treated as near-term revenue with certainty.
• Any legal or regulatory conclusion must identify the governing authority, rule, or regulation relied on, rather than stating the conclusion in shorthand.

4. Analytical scaffolds

• Start by mapping the source set into: market data, customer and commercial contracts, reimbursement and regulatory items, pipeline and product development, precedent transactions, and any internal-versus-external inconsistencies.
• For market size and growth:
  • identify the base year used by the sell-side materials;
  • compare the stated figures to independent research;
  • note whether differences are methodological, timing-based, or substantive.
• For market share:
  • compare the stated share with independent sources;
  • state both figures and assess which is more credible and why.
• For customer concentration:
  • identify the largest customer relationships and the share of revenue they represent;
  • flag any contract expiring during or shortly after the contemplated transaction period;
  • explain the revenue exposure and any negotiating leverage or retention risk.
• For reimbursement changes:
  • identify each rate adjustment and the affected revenue base;
  • show the annual revenue effect and the resulting EBITDA effect after any offsets disclosed in the source materials.
• For laboratory-developed test change:
  • identify the governing rule and any litigation or implementation phase;
  • assess whether the timing makes the near-term impact smaller than the headline suggests.
• For EU certification risk:
  • determine whether current or pipeline products need additional certification;
  • assess the probability and timing risk associated with constrained review capacity.
• For precedent transactions:
  • identify older or unusual deals that may inflate the median;
  • present an adjusted benchmark alongside the unadjusted one and explain the valuation implication.
• For pipeline products:
  • state the actual development stage;
  • align commercialization timing to that stage;
  • discount revenue expectations where success is still uncertain.
• For OTC growth:
  • test whether recent volume growth appears durable or tied to one-time demand, stocking, or channel effects.
• Where the source materials conflict, prefer the more current, more directly supported, and methodologically consistent source, but explain the reconciliation rather than silently choosing one.

5. Vertical / structural / temporal relationships

• Track how commercial concentration, reimbursement pressure, and regulatory timing interact across the deal timeline.
• Distinguish immediate, near-term, and longer-dated impacts so that a risk with delayed effect is not presented as an immediate earnings hit.
• When a customer renewal, reimbursement cut, or certification delay overlaps with the expected closing or integration window, state the timing overlap and the practical consequence.
• If the source materials contain both external market data and internal planning assumptions, flag any divergence by topic and explain whether the gap is material or cosmetic.
• If multiple products or geographies are involved, compare them on the same basis before drawing a portfolio-level conclusion.

6. Output structure conventions

• Write the deliverable as an industry and market analysis memo with sectioned discussion by topic.
• Include a compact market data comparison table showing sell-side figure, independent figure, and a short assessment.
• Include a customer concentration section that identifies the relevant customer exposure and any near-term contract timing issue.
• Include a regulatory and reimbursement section that translates headline items into financial impact where possible.
• Include a precedent transactions section that states both the raw and recency-adjusted valuation benchmark when needed.
• Include a short section on pipeline and commercialization risk that ties product stage to revenue realism.
• End with a concise recommendations section that turns the diligence findings into action items for the investment committee or deal team, assigning each item to a responsible role and timing it to the deal process.
• Keep the memo analytical and source-based; do not pad with generic industry background that does not inform the acquisition decision.